SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma - Quaterly Results

10 May 2023 Evaluate
The revenue zoomed 16.46% to Rs. 2099.01 millions for the quarter ended March 2023 as compared to Rs. 1802.34 millions during the corresponding quarter last year.The Total revenue for the quarter ended March 2023 of  Rs. 659.31  millions  grew by 47332.37% from Rs. 1.39 millions.OP of the company witnessed a marginal growth to 414.17 millions from 312.25 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 2099.01 1802.34 16.46 6658.98 5569.74 19.56 6658.98 5569.74 19.56
Other Income 17.29 17.47 -1.03 194.31 90.03 115.83 194.31 90.03 115.83
PBIDT 414.17 312.25 32.64 1030.49 662.62 55.52 1030.49 662.62 55.52
Interest 74.84 44.59 67.84 322.26 320.12 0.67 322.26 320.12 0.67
PBDT 731.43 267.66 173.27 1100.33 342.50 221.26 1100.33 342.50 221.26
Depreciation 72.12 266.27 -72.91 547.86 870.21 -37.04 547.86 870.21 -37.04
PBT 659.31 1.39 47332.37 552.47 -527.71 -204.69 552.47 -527.71 -204.69
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 659.31 1.39 47332.37 552.47 -527.71 -204.69 552.47 -527.71 -204.69
Equity 408.16 408.16 0.00 408.16 408.16 0.00 408.16 408.16 0.00
PBIDTM(%) 19.73 17.32 13.89 15.48 11.90 30.08 15.48 11.90 30.08

Orchid Pharma Share Price

564.10 -3.40 (-0.60%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×